| Literature DB >> 15935717 |
Abstract
A tuberculosis (TB) vaccine candidate, Mtb72, was developed following an antigen discovery program involving a combination of expression cloning strategies and evaluation of human immune responses. Adjuvant selection was also performed, resulting in the prioritization of AS02A and AS01B, and an industrial process for vaccine production was developed. Safety, immunogenicity, and protection studies in mice, guinea pigs, rabbits, and monkeys supported the initiation of clinical development of Mtb72f in AS02A.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15935717 DOI： 10.1016/j.micinf.2005.03.011
Source DB: PubMed Journal: Microbes Infect ISSN： 1286-4579 Impact factor: 2.700